Evaluation of a Novel Bayesian Method for Individualizing Theophylline Dosage
暂无分享,去创建一个
M. Oellerich | M. Oellerich | G. Sybrecht | U. Stein | G. W. Sybrecht | B. Schneider | B. Schneider | U. Stein
[1] J J Schentag,et al. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. , 1979, Journal of pharmaceutical sciences.
[2] David L. Horwitz,et al. ANALYSIS OF BIOMEDICAL DATA BY TIME-SHARING COMPUTERS. I. NON-LINEAR REGRESSION ANALYSIS. , 1970 .
[3] L. Lesko. Dose-dependent kinetics of theophylline. , 1986, The Journal of allergy and clinical immunology.
[4] J. Jenne,et al. Pharmacokinetics of theophylline; Application to adjustment of the clinical dose of aminophylline , 1972, Clinical pharmacology and therapeutics.
[5] M. Gibaldi,et al. Pharmacokinetics, Second Edition , 1982 .
[6] A. Vaida,et al. Evaluation of the effect of nonlinear kinetics on dosage adjustments of theophylline. , 1983, Therapeutic drug monitoring.
[7] H. Reddel,et al. Dose-dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease. , 1982, British journal of clinical pharmacology.
[8] H. Chrystyn,et al. The accuracy of a pharmacokinetic theophylline predictor using once daily dosing. , 1987, British journal of clinical pharmacology.
[9] M. Gibaldi,et al. Prediction of Maintenance Dose Required to Attain a Desired Drug Concentration at Steady-state From a Single Determination of Concentration After an Initial Dose , 1980, Clinical pharmacokinetics.
[10] R. W. Foster,et al. Comparative evaluation of six techniques for determining the Michaelis‐Menten parameters relating phenytoin dose and steady‐state serum concentrations , 1979, The Journal of pharmacy and pharmacology.
[11] J. Miners,et al. Nonlinear Metabolic Disposition of Theophylline , 1984, Therapeutic drug monitoring.
[12] L B Sheiner,et al. Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.